KRAS and non-small cell lung carcinoma: In 2018, a phase 1B study evaluated the multitargeted Janus kinase/TANK-binding kinase 1 (TBK1) inhibitor momelotinib combined with the mitogen/extracellular signal-related kinase (MEK)1/MEK2 inhibitor trametinib in patients with platinum-treated, refractory, metastatic, K-RAS-mutant NSCLC.